Theravance Biopharma (NASDAQ:TBPH) Shares Pass Above 50 Day Moving Average – Should You Sell?

Theravance Biopharma, Inc. (NASDAQ:TBPH) shares passed above its 50 day moving average during trading on Friday . The stock has a 50 day moving average of $14.03 and traded as high as $14.59. Theravance Biopharma shares last traded at $14.28, with a volume of 220,285 shares.

Analyst Ratings Changes

Several analysts recently commented on the company. B. Riley assumed coverage on Theravance Biopharma in a report on Friday, September 12th. They issued a “buy” rating and a $28.00 price objective for the company. BTIG Research lifted their price objective on Theravance Biopharma from $24.00 to $25.00 and gave the stock a “buy” rating in a report on Friday, June 27th. Zacks Research lowered Theravance Biopharma from a “strong-buy” rating to a “hold” rating in a report on Monday, September 15th. Wall Street Zen raised Theravance Biopharma from a “hold” rating to a “strong-buy” rating in a report on Saturday, August 16th. Finally, Weiss Ratings reaffirmed a “hold (c)” rating on shares of Theravance Biopharma in a report on Wednesday, October 8th. Two research analysts have rated the stock with a Strong Buy rating, two have assigned a Buy rating and two have given a Hold rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Buy” and an average target price of $23.00.

Theravance Biopharma Stock Up 1.0%

The company has a fifty day simple moving average of $14.03 and a 200-day simple moving average of $11.62. The firm has a market cap of $719.16 million, a P/E ratio of 59.50 and a beta of -0.03.

Institutional Trading of Theravance Biopharma

Several hedge funds have recently bought and sold shares of TBPH. Vanguard Group Inc. boosted its stake in shares of Theravance Biopharma by 3.5% in the first quarter. Vanguard Group Inc. now owns 2,080,463 shares of the biopharmaceutical company’s stock worth $18,579,000 after acquiring an additional 69,919 shares during the period. Park West Asset Management LLC boosted its stake in shares of Theravance Biopharma by 0.6% in the first quarter. Park West Asset Management LLC now owns 1,804,244 shares of the biopharmaceutical company’s stock worth $16,112,000 after acquiring an additional 11,256 shares during the period. Geode Capital Management LLC boosted its stake in shares of Theravance Biopharma by 0.4% in the second quarter. Geode Capital Management LLC now owns 893,983 shares of the biopharmaceutical company’s stock worth $9,863,000 after acquiring an additional 3,416 shares during the period. Bank of America Corp DE boosted its stake in shares of Theravance Biopharma by 16.5% in the second quarter. Bank of America Corp DE now owns 539,645 shares of the biopharmaceutical company’s stock worth $5,952,000 after acquiring an additional 76,417 shares during the period. Finally, Assenagon Asset Management S.A. boosted its stake in shares of Theravance Biopharma by 1,629.4% in the third quarter. Assenagon Asset Management S.A. now owns 414,715 shares of the biopharmaceutical company’s stock worth $6,055,000 after acquiring an additional 390,735 shares during the period. Institutional investors own 99.10% of the company’s stock.

About Theravance Biopharma

Theravance Biopharma, Inc is a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small molecule drugs designed to better meet patient needs. Its research is focused in the areas of inflammation and immunology.
In pursuit of its purpose, Theravance Biopharma applies insights and innovation at each stage of its business and utilizes its internal capabilities and those of partners around the world.